Innovation is and has been a cornerstone of our commitment to advancing dermatology since the creation of Galderma in 1981. Today, we reaffirm this commitment with a clear, concerted focus on developing innovative technologies, products and services to protect, treat and enhance the skin.
Galderma stands out as one of the few companies capable of inventing, developing and bringing to market novel dermatological solutions for patient needs and consumer benefits. Our best-in-class R&D pipeline features ambitious, differentiated projects that target strategic therapeutic areas across Aesthetics, Consumer Care and Prescription medicine. We are planning 22 new product launches across global business units and geographies in 2021, alongside significant pipeline investment, building on our strong track record of first-to-market innovation.
In addition to our in-house resources and capabilities, we are a partner of choice for academic and industrial research collaboration around the world. Collaborations enable access to complementary perspectives, diverse areas of expertise, emerging technologies and disruptive concepts. They extend our ability to serve the needs of healthcare professionals and patients, helping to advance global health.
EXAMPLES OF INNOVATION ACROSS OUR GLOBAL BUSINESS UNITS
AESTHETICS
Galderma has decades of pioneering Aesthetics innovations, specialising in hyaluronic acid fillers, neuromodulators and collagen biostimulators. In 2022 and beyond, we will continue to bring premium product innovations to the market and have an exciting portfolio.
We were the first company to develop a hyaluronic filler, with the launch of Restylane over 25 years ago. Since then, we have continued to bring new innovations and improved technology and products to the range and it is now the most diverse range of HA fillers on the market, covering all possible patients’ needs. For example, in 2021, we had two launches, Restylane Eyelight, a targeted treatment solution to combat under eye shadows and Restylane Defyne, for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21.
Sculptra, the original collagen stimulator is CEE marked since 1999 and is the only FDA-approved biostimulator. Sculptra stimulates the skin’s own collagen production, gradually restoring its firmness to achieve natural-looking results that last for more than two years. In 2021, we introduced a new reconstitution (8ml) with improved safety profile, easier to use and with optional lidocaine for additional patient comfort. The R&D team continue to work on new indications and formulations to bring new innovations to the market.
In Neuromodulators, Galderma continues to be a leading player with Azzalure/Dysport and in 2022 are rolling out the launch of Alluzience across Europe, the first ready-to-use liquid neuromodulator and the first major innovation in the space in over a decade. Galderma is also developing a novel, ready-to-use liquid neuromodulator (QM-1114 (relabotulinumtoxinA)) for the treatment of glabellar lines and lateral canthal lines which is currently in late stage development.
PRESCRIPTION MEDICINE
Nemolizumab is a first-in-class humanized monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.[i] IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and PN, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus (itching). Despite the significant unmet medical needs, there are currently no registered therapeutic options for PN.
CONSUMER CARE
We continue to innovate across our portfolio to improve how we can meet the skincare needs of consumers. We partner with dermatologists in identifying and developing innovations that they love to recommend to patients. An example of this is across Cetaphil where we continue to extend the product range to improve the lives of consumers with sensitive skin through outstanding everyday cleansers & moisturizers supplemented with products to meet the needs of specific skin conditions, such as acne, eczema and rosacea, where we have significant expertise and heritage.
[i] Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatology Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205
